<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bevacizumab (Bev), a monoclonal antibody to vascular endothelial growth factor (VEGF), is used in combination with chemotherapy for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of Bev on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> have been well described, but the direct effect of Bev on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>This study was carried out to determine the molecular and phenotypic changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells after <z:hpo ids='HP_0011010'>chronic</z:hpo> Bev exposure in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were chronically exposed (3 months) to Bev in vitro to develop Bev-adapted (Bev-A) cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>Vascular endothelial growth factor family members were determined by reverse transcription-polymerase chain reaction and western blotting </plain></SENT>
<SENT sid="5" pm="."><plain>Migration and invasion was determined using standard in vitro assays </plain></SENT>
<SENT sid="6" pm="."><plain>Intravenous injection of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells was carried out to evaluate metastatic potential in mice </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Bevacizumab-adapted cells were found to be more migratory and invasive than control cells (P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Bevacizumab-adapted cells showed higher levels of VEGF-A, -B, -C, placental growth factor (PlGF), VEGF receptor-1 (VEGFR-1) and phosphorylation of VEGFR-1 </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, treatment with SU5416, a VEGFR <z:chebi fb="0" ids="38637">protein tyrosine kinase inhibitor</z:chebi>, led to significantly decreased cell migration in vitro (P&lt;0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Bevacizumab-adapted cells were more metastatic in vivo (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0011010'>Chronic</z:hpo> exposure of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells to Bev (1) increased expression of VEGF-A, -B, -C, PlGF, VEGFR-1 and VEGFR-1 phosphorylation, (2) increased <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumour cell migration</z:e> and invasion, and (3) metastatic potential in vivo </plain></SENT>
<SENT sid="12" pm="."><plain>Our study shows the functional significance of autocrine VEGF signalling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
</text></document>